New Analysis Confirms FDA-approved Alprolix Benefits in Patients with Severe Hemophilia B
A new analysis of two Phase 3 clinical trials confirms that extending preventive treatment with Alprolix is safe and leads to markedly decreases in bleeding episodes of severe hemophilia B patients. The results were recently presented at the 59th Annual Meeting of the American Society of Hematology (ASH) in…